Company intelligence / Profile preview

IR-MED

Rosh Pina, Northern District, Israel

Ownership: Private
Employees: ~15
Development stage: Other

Overview

PressureSafe demonstrated ~90-94% accuracy/sensitivity in preemptively assessing pressure injury risk prior to skin breakdown, including in patients of all skin tones; further interim and multicenter clinical studies ongoing. DiaSafe and additional pipeline products are in development/preclinical stages, with a $500,000 grant and increasing external validation and research presentations.

Therapeutic areas: Infectious DiseasesEndocrinologyDermatologyOther
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

HCA Healthcare (clinical studies, research partnerships)Galen College of Nursing (research site and data sharing)possibly others via grant-funded development and clinical collaborations

Beyond the preview

Go deeper on IR-MED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IR-MED.

Explore the full profile